Disheartening data from ResMed’s sleep apnea study gives Philips pause for thought
This article was originally published in Clinica
Stocks in the respiratory disorders specialist ResMed have yet to recover after a thrashing last week following news that the company’s Phase IV trial to assess the benefits of sleep apnea therapy in heart failure patients had missed its primary endpoint.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.